CD38 and plasma cell myeloma: In addition, the surface expression of CD38 in myeloma cells is reduced after daratumumab exposure due to the transfer of CD38-daratumumab complexes from myeloma cells to monocytes and granulocytes by a process called trogocytosis [136].